Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Cooking Pressure

<< Previous

Bullboard Posts

Next >>

Comment by YegJeeberon Feb 01, 2023 11:19pm

262 Views

Post# 35261333

RE:Cooking Pressure

When this does the big ka-pop, there won't be anything left to leave on the table. Trading halted, news released of buyout, packages sent to shareholders outlining offering, period of voting ensues, votes are tabulated, acceptance is broadcast, outstanding shares of ONCY are replaced in shareholder accounts with BO$ / Outstanding shares x shares held by investors OR equivalent value of BP buyers shares. At that point my fiancee and I rethink our honeymoon plans for this summer. . GLTA!!

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features